Mallinckrodt (MNK) Reaches New 12-Month High and Low at $13.61

Shares of Mallinckrodt (NYSE:MNK) hit a new 52-week high and low during trading on Thursday . The company traded as low as $13.61 and last traded at $13.76, with a volume of 4423866 shares changing hands. The stock had previously closed at $14.90.

MNK has been the topic of a number of research analyst reports. Cantor Fitzgerald set a $42.00 price target on shares of Mallinckrodt and gave the company a “buy” rating in a research report on Monday, January 8th. Zacks Investment Research raised shares of Mallinckrodt from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 9th. ValuEngine cut shares of Mallinckrodt from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Goldman Sachs reissued a “hold” rating on shares of Mallinckrodt in a research report on Tuesday, December 26th. Finally, Canaccord Genuity set a $24.00 price objective on shares of Mallinckrodt and gave the stock a “hold” rating in a research report on Tuesday, December 26th. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have assigned a buy rating to the company. Mallinckrodt presently has a consensus rating of “Hold” and a consensus price target of $33.89.

The stock has a market cap of $1,199.41, a price-to-earnings ratio of 1.84, a PEG ratio of 0.35 and a beta of 1.12. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.85 and a current ratio of 2.18.



Mallinckrodt (NYSE:MNK) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $2.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.29. Mallinckrodt had a net margin of 66.25% and a return on equity of 13.43%. The business had revenue of $792.30 million for the quarter, compared to analysts’ expectations of $769.91 million. During the same quarter last year, the firm earned $1.91 EPS. The firm’s revenue for the quarter was down 4.5% compared to the same quarter last year. equities analysts predict that Mallinckrodt will post 6.17 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. LMR Partners LLP bought a new position in Mallinckrodt in the 4th quarter valued at about $2,630,000. Fox Run Management L.L.C. bought a new position in Mallinckrodt in the 4th quarter valued at about $1,064,000. Virtu Financial LLC lifted its position in Mallinckrodt by 78.2% in the 4th quarter. Virtu Financial LLC now owns 16,308 shares of the company’s stock valued at $368,000 after acquiring an additional 7,159 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in Mallinckrodt by 6.9% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 433,563 shares of the company’s stock valued at $16,203,000 after acquiring an additional 27,908 shares in the last quarter. Finally, California Public Employees Retirement System lifted its position in Mallinckrodt by 25.9% in the 4th quarter. California Public Employees Retirement System now owns 332,306 shares of the company’s stock valued at $7,497,000 after acquiring an additional 68,336 shares in the last quarter. 97.38% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was first reported by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://dakotafinancialnews.com/2018/04/14/mallinckrodt-mnk-reaches-new-12-month-high-and-low-at-13-61.html.

About Mallinckrodt

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply